Fig 1: Molecular mechanism of action. Platycodin D (PD) upregulated miR-129-5p cells to inhibit PABPC1 and reduce the phosphorylation of PI3K and AKT, thus suppressing proliferation while promoting apoptosis of bladder cancer cells.
Fig 2: Effects of LINK-A overexpression on Akt signaling. (A) p-Akt and Akt protein expression, quantified by western blot analysis. (B) LINK-A expression in cells treated with Akt activator SC79 at 5 and 10 µg/ml. *P<0.05. LINK-A, long intergenic non-coding RNA for kinase activation; C, control; NC, negative control; p-, phosphorylated.
Fig 3: The ILEI/LIFR complex promotes EMT through the Akt and ERK pathways in vivo and in vitro. A, B WB analysis of Akt, p-Akt and ERK, and p-ERK in vivo. C The value of p-Akt to Akt and p-ERK to ERK in mice. D, E WB analysis of Akt, p-Akt and ERK, and p-ERK in vitro. F The value of p-Akt to Akt and p-ERK to ERK in vitro, *p < 0.05, #p < 0.05
Fig 4: Down-regulation of HIF-1a inhibited PI3K/AKT pathway and VEGFThis figure shows the effects of HIF-1a siRNA silencing on expression of VEGF (A) and phosphorylation and expression of AKT (B). In (A,B) the upper part is Western blot results and the lower part is the normalized expression. HIF-1a siRNA silencing inhibited VEGF expression and AKT phosphorylation. *, P<0.05.
Fig 5: TRKB RNA interference of Aß-GFP SH-SY5Y cells. (A) Experimental flow chart. On day 1, Aß-GFP SH-SY5Y cells were plated with retinoic acid (RA; 10 µM). On day 2, the cells were infected with lentivirus-expressing TRKB-specific or scrambled shRNA. At 24 h post-infection, LM-031 or LMDS-1 to -4 (5 µM) was added to the cells for 8 h, followed by induction of Aß-GFP expression (Dox, 5 µg/ml) for 6 days. On day 9, TRKB and neurite outgrowth analyses were performed. Western blot analysis of (B) TRKB, (C) p-ERK (T202/Y204), ERK, p-AKT (S473), AKT, p-CREB (S133), and CREB in compound-treated cells infected with TRKB-specific or scrambled shRNA-expressing lentivirus (n = 3). GAPDH was used as a loading control. To normalize, the relative protein level of uninduced cells was set at 100%. (D) Microscopic images and neurite outgrowth (length, process and branch) assay of Aß-GFP-expressing cells with TRKB-specific or scrambled shRNA, and with or without LM-031 or analogs (5 µM) treatments (n = 3). TUBB3 staining (yellow) was used to quantify the extent of neurite outgrowth. Nuclei were counterstained with DAPI (blue). Also shown were segmented images with multi-colored mask to assign each outgrowth to a cell body for quantification. In uninduced cells, processes and branches are indicated with red and white arrows, respectively. P values: comparisons between induced vs. uninduced cells (###P < 0.001), compound-treated vs. untreated (induced) cells (***P < 0.001), or TRKB shRNA-treated vs. scrambled shRNA-treated cells (&P < 0.05, &&P < 0.01, &&&P < 0.001). (one-way ANOVA with a post hoc Tukey test).
Supplier Page from Abcam for Anti-AKT1 + AKT2 + AKT3 antibody